Company
Apellis Pharmaceuticals
Apellis Pharmaceuticals has 5 drugs tracked on RxWires: 2 in Phase 3, 1 in Phase 2/3, 1 in Phase 2, 1 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Pegcetacoplan | Phase 3 | C3G |
| APL-2, Pegcetacoplan | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| APL2 | Phase 2/3 | FSGS |
| APL-3007, pegcetacoplan (APL-2) | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| APL-9 | Phase 1/2 | COVID |
Latest
No recent events.
Follow Apellis Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.